$KMDA

Tsur David sold 177,173 shares of KAMADA LTD (KMDA) at an average of $8.26 ($8.26–$8.28, $1.46M total) across 3 trades over 2026-09-07 to 2026-09-09.

Kamada reported Q2 2026 earnings with record revenues of $54.9M (+23% YoY) and adjusted EBITDA of $14.1M (+29% YoY). The company reiterated its 2026 guidance of $200M-$205M in revenues and $50M-$53M in adjusted EBITDA. Growth is driven by existing products, with plans to accelerate through acquisitions and expanded distribution. Key products like KEDRAB and GLASSIA showed strong demand, and the company expects plasma sales to begin by year-end.

Kamada Ltd. reported Q2 2026 results driven by double-digit growth in its commercial portfolio, led by KEDRAB. Management reiterated 2026 revenue guidance of $200 million to $205 million and a 26% adjusted EBITDA margin. It expects plasma sales to start in Q4, supported by a 3-year $50 million supply deal, plus biosimilar expansion and M&A. CFO Chaime Orlev will leave end-2026.

Kamada Ltd. (NASDAQ: KMDA) reported record first-half 2026 results: revenues $100.2M (+13% YoY) and adjusted EBITDA $25.7M (+14% YoY), with net income $13.4M (+18%). Q2 revenues were $54.9M (+23%) and adjusted EBITDA $14.1M (+29%). It affirmed 2026 guidance: revenues $200M-$205M and adjusted EBITDA $50M-$53M, and signed a ~3-year ~$50M plasma supply agreement.

KAMADA LTD (KMDA) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance ● Record-High First Half Revenues of $100.2 Million, up 13% Year-over-Year

Kamada (Nasdaq: KMDA; TASE: KMDA) said it signed a three-year normal source plasma supply agreement with a biopharmaceutical company. The deal is expected to generate about $50 million in revenue over three years, with initial commercial sales recorded in Q4 2026. Kamada noted its Texas collection centers are ramping to support the supply.

Kamada (NASDAQ: KMDA) said three posters at the 2026 ISHLT meeting presented analyses of CYTOGAM (CMV immune globulin) in CMV high-risk lung transplant recipients. A retrospective review linked CYTOGAM prophylaxis with better clinical outcomes, paired blood-cell data showed reduced innate immune activation, and a non-clinical model reported blunted lung injury and improved mortality.

Kamada (KMDA) reported strong FY25 revenue growth and increased net income, despite missing Q4 consensus estimates. Management reaffirmed robust 2026 guidance and announced a new annual dividend policy, signaling confidence in future growth. The company trades at a discounted valuation, with biosimilars expansion and a strong balance sheet supporting its investment appeal.

Kamada's shares saw a decline following the announcement that the company has halted its Phase 3 study of an inhaled Alpha-1 Antitrypsin (AAT) therapy. The decision to stop the clinical trial is a significant setback for the development of this particular AAT treatment.

Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.